These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36127767)

  • 1. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
    Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
    Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
    Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
    Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
    Javle M; Roychowdhury S; Kelley RK; Sadeghi S; Macarulla T; Weiss KH; Waldschmidt DT; Goyal L; Borbath I; El-Khoueiry A; Borad MJ; Yong WP; Philip PA; Bitzer M; Tanasanvimon S; Li A; Pande A; Soifer HS; Shepherd SP; Moran S; Zhu AX; Bekaii-Saab TS; Abou-Alfa GK
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):803-815. PubMed ID: 34358484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
    Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
    Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
    Vogel A; Sahai V; Hollebecque A; Vaccaro GM; Melisi D; Al Rajabi RM; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Lihou CF; Zhen H; Veronese ML; Abou-Alfa GK
    ESMO Open; 2024 Jun; 9(6):103488. PubMed ID: 38838500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
    Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE
    Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
    Uson PLS; Bearss J; Babiker HM; Borad M
    Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
    Lindley A; Prager G; Bitzer M; Burn TC; Lihou CF; Croft E
    Cancer Res Treat; 2024 Jul; 56(3):847-855. PubMed ID: 38351684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
    J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
    Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
    J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without
    Bibeau K; Féliz L; Lihou CF; Ren H; Abou-Alfa GK
    JCO Precis Oncol; 2022 Apr; 6():e2100414. PubMed ID: 35544727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemigatinib Is Active in Some
    Cancer Discov; 2020 May; 10(5):639. PubMed ID: 32245820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Futibatinib for
    Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
    N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicogenomic Analysis of
    Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
    Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration.
    Chen ZR; Chueh CH; Chiang NJ; Tsai YW
    Cost Eff Resour Alloc; 2023 Sep; 21(1):61. PubMed ID: 37697368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
    Gandhy SU; Casak SJ; Mushti SL; Cheng J; Subramaniam S; Zhao H; Zhao M; Bi Y; Liu G; Fan J; Adeniyi O; Charlab R; Kufrin D; Thompson MD; Jarrell K; Auth D; Lemery SJ; Pazdur R; Kluetz PG; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Oct; 29(20):4027-4031. PubMed ID: 37289037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.